GLP-3  is the “3rd Agonist” and currently the most in the metabolic pipeline. Often referred to as “Triple G,” it is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Is known to help eliminate white visceral fat, help with Diabetes, Lower Blood pressure, Solve up to 80% Fatty Liver, while still undergoing readouts have been record-breaking.

Core Benefits and Clinical Data The primary draw of GLP-3 is its “triple action” mechanism. By adding glucagon receptor agonism to the GLP-1/GIP combination (found in tirz-2), it increases energy expenditure and targets liver fat more aggressively.

Unprecedented: In Phase 2 clinical trials, GLP-3 demonstrated the highest weight effectiveness percentages ever seen in pharmacological treatment:

One of RET-3’s standout features is its effect on liver fat, likely due to the glucagon component:

• Fat Reduction: In specific sub-studies, patients saw an average reduction in liver fat of over 80%.
• Resolution: Over 85% of patients with non-alcoholic fatty liver disease (now called MASLD) saw their liver fat levels return to normal ranges within 48 weeks.

Comparison Table: GLP-3 vs. Predecessors

• Feature | GLP-1  | GLP-2 | GLP-3
• Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon
• Avg. Fat Loss | ~15% | ~21% | ~24% +
• Primary Focus | Appetite | Appetite + Insulin | Appetite + Insulin + Energy Burn